Zacks: Analysts Anticipate Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Will Announce Earnings of -$0.40 Per Share

Brokerages forecast that Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating) will post ($0.40) earnings per share for the current quarter, Zacks reports. Two analysts have issued estimates for Kiniksa Pharmaceuticals’ earnings, with estimates ranging from ($0.52) to ($0.27). Kiniksa Pharmaceuticals reported earnings per share of ($0.72) during the same quarter last year, which indicates a positive year-over-year growth rate of 44.4%. The company is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Kiniksa Pharmaceuticals will report full year earnings of ($1.82) per share for the current year, with EPS estimates ranging from ($2.05) to ($1.58). For the next fiscal year, analysts forecast that the company will post earnings of ($1.40) per share, with EPS estimates ranging from ($1.55) to ($1.25). Zacks’ EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Kiniksa Pharmaceuticals.

Kiniksa Pharmaceuticals (NASDAQ:KNSA – Get Rating) last released its quarterly earnings data on Tuesday, February 22nd. The company reported ($0.53) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.09). The business had revenue of $18.75 million for the quarter, compared to the consensus estimate of $16.32 million.

A number of analysts have commented on KNSA shares. Bank of America cut their price objective on shares of Kiniksa Pharmaceuticals from $37.00 to $34.00 and set a “buy” rating for the company in a report on Wednesday, December 29th. Zacks Investment Research cut shares of Kiniksa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 24th.

KNSA stock traded down $0.59 during mid-day trading on Monday, reaching $10.82. The company’s stock had a trading volume of 324,515 shares, compared to its average volume of 352,428. The stock has a market cap of $747.71 million, a PE ratio of -4.70 and a beta of -0.02. Kiniksa Pharmaceuticals has a fifty-two week low of $9.05 and a fifty-two week high of $17.71. The company’s 50 day moving average price is $10.43.

Several large investors have recently bought and sold shares of KNSA. Invesco Ltd. purchased a new position in shares of Kiniksa Pharmaceuticals during the 2nd quarter worth approximately $153,000. Morgan Stanley boosted its position in shares of Kiniksa Pharmaceuticals by 115.5% during the 2nd quarter. Morgan Stanley now owns 383,934 shares of the company’s stock worth $5,348,000 after purchasing an additional 205,803 shares during the period. M&T Bank Corp boosted its position in shares of Kiniksa Pharmaceuticals by 88.3% during the 3rd quarter. M&T Bank Corp now owns 20,501 shares of the company’s stock worth $234,000 after purchasing an additional 9,611 shares during the period. SG Americas Securities LLC purchased a new position in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $211,000. Finally, M&G Investment Management Ltd. purchased a new position in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $1,568,000. 43.01% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Company Profile (Get Rating)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Recommended Stories